Cancer markers are molecules produced by cancer cells which may serve to identify the
presence of cancer. Cancer markers can be differentiated as serum-based, radiology-based …

Background Pembrolizumab prolongs progression-free and overall survival among patients
with advanced melanoma and recurrence-free survival in resected stage III disease …

Skin cancer is the most commonly diagnosed cancer worldwide. Understanding the natural
history of skin cancer will provide a framework for the creation of prevention and control …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Background Patients with stage IIB or IIC melanoma who undergo surgery alone are at a
substantial risk for disease recurrence. Adjuvant pembrolizumab significantly improved …

The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient
and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond …

Abstract Background Immune checkpoint inhibitors (ICIs) have substantially improved
overall survival in patients with advanced melanoma; however, the lack of biomarkers to …

Prognostic analysis for early-stage (stage I/II) melanomas is of paramount importance for
customized surveillance and treatment plans. Since immune checkpoint inhibitors have …

PURPOSE Non-V600 mutations comprise approximately 35% of all BRAF mutations in
cancer. Many of these mutations have been identified as oncogenic drivers and can be …

Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still
constrained by lack of response and toxicity. Biomarkers of response may facilitate drug …